Furthermore, selpercatinib resulted in prolonged PFS compared with conventional standard multi-kinase inhibitors in patients with treatment-naïve RET mutation-positive MTC in the phase 3 randomized controlled trial (LIBRETTO-531). This evidence concerns the gene RET and medullary thyroid gland carcinoma.